摘要
目的比较静脉用蔗糖铁注射液与口服多糖铁复合物对使用促红细胞生成素(EPO)维持性血液透析患者的肾性贫血的疗效与安全性,以减少EPO的用量。方法我院血液净化中心维持性血液透析的贫血患者40例,随机分为静脉组和口服组,各20例。静脉组:蔗糖铁100 mg,在透析开始后2 h,通过透析器静脉端注射至少5 min,每周1次。口服组:口服多糖铁复合物胶囊300 mg,1次/d。总疗程为12周。比较治疗前、后患者的血红蛋白(Hb)、红细胞压积(Hct)、血清铁蛋白(SF)、血清转铁蛋白饱和度(TSAT)、EPO用量及不良反应。结果①治疗前两组年龄、性别比例、体重、EPO用量、Hb、Hct、SF、TSAT水平差异无统计学意义(P>0.05)。②用药4周时,两组Hb、Hct、SF、TSAT均明显升高(P<0.05);治疗4、8、12周时,静脉组Hb、Hct、SF、TSAT升高幅度明显高于口服组,差异有统计学意义(P<0.05)。③静脉组在用药过程中无不良反应发生,口服组出现消化道不良反应8例。④治疗8、12周时,静脉组应用EPO用量低于治疗前及口服组(P<0.05)。结论静脉用蔗糖铁可有效纠正维持性透析患者肾性贫血的铁缺乏,改善贫血,安全性好,且能减少EPO用量。
Objective To compare the efficacy and safety of intravenous iron sucrose with oral polysaccharide iron complex in erythropoietin-treated maintenance hemodialytic patients.Methods Forty maintenance hemodialytic patients were divided into two groups randomly and treated with intravenous iron sucrose and oral polysaccharide iron complex respectively.Intravenous iron sucrose group（intravenous group）：receiving intravenous iron sucrose 100 mg once a week;oral medication group（oral group）：receiving polysaccharide iron complex 300 mg once daily for 12 weeks.The levels of serum ferritin（SF）,transferrin saturation（TSAT）,hemoglobin（Hb）,hemotocrit（Hct）were examined before treatment and at 4,8 and 12 weeks after treatment.Results ①The age,sex,weight,dose of EPO,Hb,Hct,SF and TSAT of the 2 groups had no significant difference before treatment（P0.05）.②Compared with baseline levels,the levels of Hb,Hct,SF and TSAT of all patients significantly increased at 4 weeks after treatment（P0.05）;the Hb,Hct,SF,and TSAT levels of intravenous group were significantly higher than those of oral group（P0.05）.③No adverse event was found in intravenous group,while there were 12 cases with adverse gastrointestinal effects in oral group.④Doses of EPO of intravenous group at 8,12 weeks after treatment decreased（P0.05）,and they were lower than those of oral group（P0.05）.Conclusion Intravenous iron sucrose is effective and safe in improving iron deficiency and renal anemia in maintenance hemodialytic patients,and it can reduce the dose of EPO.
出处
《实用药物与临床》
CAS
2012年第4期206-208,共3页
Practical Pharmacy and Clinical Remedies
